1. Japan Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
D&M Co., Ltd.

D&M Co., Ltd.

TTSE:189A
1,054.00
JPY
-22.00
(-2.04%)
2.17BMarket Cap
Jan 08Next Earn
D&M Co., Ltd.
TSE:189A
(Tokyo Stock Exchange)

Recent

price

1,054.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
2026
TTM
JPY
606.55
724.28
775.43
672.92
711.34
- -
Revenue per Share
94.97
111.91
115.63
98.85
97.18
- -
Basic EPS, GAAP
591.08
-1,438.66
-511.75
-45.81
-448.23
- -
Free Cash Flow per Basic Share
5
5
5
3.43
19.82
- -
Dividend per Share
443.66
521.23
601.51
934.93
1,013.79
1,013.79
Book Value per Share
442.4
520.24
600.71
934.45
1,011.34
1,011.34
Tangible Book Value per Share
2
2
2
2
2
2
Basic Weighted Avg Shares
930
1,111
1,190
1,503
1,624
- -
Sales/Revenue/Turnover
25.21
21.28
23.63
19.93
16.77
- -
Operating Margin (%)
4
6
7
11
15
- -
Depreciation Expense
146
172
177
221
222
- -
Net Income, GAAP
37.85
31.41
35.38
26.47
28.58
- -
Effective Tax Rate (%)
15.66
15.45
14.91
14.69
13.66
- -
Profit Margin (%)
1,442
1,779
1,684
2,757
2,881
2,881
Working Capital
660
758
534
806
931
931
LT Debt
938
1,102
1,272
2,120
2,349
2,349
Total Equity
- -
2.4
2.19
2.48
1.99
- -
Return on Invested Capital (%)
- -
2.57
2.16
2.51
2.29
- -
Return on Capital (%)
- -
16.83
14.95
13.02
9.93
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Aug'26
Nov'26
May'26
ST Debt
- -
7,171
7,100
LT Borrowings
- -
769
925
LT Finance Leases
- -
13
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
2,096
2,446
2,169

Working Capital

JPY

•

in mil. unless spec.
Aug'26
Nov'26
May'26
Total Current Assets
- -
10,189
10,190
Cash, Cash Equivalents & STI
- -
922
636
Accounts Receivable, Net
- -
849
683
Inventories
- -
- -
- -
Total Current Liabilities
- -
7,392
7,309
Payables & Accruals
- -
- -
- -
ST Debt
- -
7,171
7,100
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
10.78%
Free Cash Flow
- -
- -
900.45%
Net Income, GAAP
- -
- -
0.52%
Sales/Revenue/Turnover
- -
- -
8.08%
Total Cash Common Dividend
- -
- -
489.87%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
290
1,190
2025
- -
- -
- -
- -
1,503
2026
- -
- -
- -
- -
1,624

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
13.61
115.63
2025
- -
- -
- -
- -
98.85
2026
- -
- -
- -
- -
97.18

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
5
2025
- -
- -
- -
- -
3.43
2026
- -
- -
- -
- -
19.82
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
D&M Company Co., Ltd. provides comprehensive management support services to medical institutions, pharmacies, nursing care, and disability welfare providers in Japan; its core offerings span three primary segments including Finance & Investment services such as medical and nursing care fee receivable factoring, leasing of medical and healthcare-related equipment, operating loans, and other financial support; Consulting & Business Renovation services encompassing organizational reform consulting, business diagnostics, cost reduction initiatives, and M&A advisory; and Human Resources & Outsourcing services featuring introductions of management and administrative personnel, temporary staffing for clerical and helper roles, foreign employment support, and various outsourcing solutions. Founded in 2015 by Akiyoshi Matsushita and Mikimasa Fujii and headquartered in Osaka, Japan, the company operates primarily within the domestic healthcare and welfare sector, targeting doctors, medical facilities, and long-term care providers with a workforce of approximately 66 employees. In recent developments, D&M Company has advanced its growth strategy through an active M&A approach to bolster its revenue base alongside service expansions for medical and welfare providers; it outlined a three-year medium-term management plan targeting consolidated sales of 3.001 billion yen by the fiscal year ending May 2028, roughly double the 1.502 billion yen achieved in the fiscal year ended May 2025, amid robust revenue growth of 26.3% in that period driven by heightened demand in HR&OS services.